Renaissance Pharma’s daretabart GD2-targeted mAb gains FDA Fast Track for high-risk neuroblastoma

Renaissance Pharma Ltd, a wholly owned subsidiary of Essential Pharma and headquartered in the UK, announced that the US FDA has granted Fast Track Designation for Daretabart (hu1418K322A), a GD2-targeted monoclonal antibody, for the treatment of high-risk neuroblastoma (HRNB). The company simultaneously confirmed Investigational New Drug (IND) clearance, enabling US initiation of the SHINE Phase II/III trial in relapsed or refractory paediatric HRNB patients. Daretabart is developed under an exclusive licence from St. Jude Children’s Research Hospital.

Fast Track Designation gives Renaissance Pharma more frequent interactions with the FDA throughout development and eligibility for rolling and accelerated review of any future marketing application. The designation does not itself confer approval or alter the evidentiary standard required.

The clinical rationale for the designation draws on a Phase II study of the antibody — then designated hu14.18K322A — evaluating it as first-line and post-consolidation therapy in HRNB patients. Updated results, published in the Journal of Clinical Oncology in February 2022, reported a three-year event-free survival (EFS) rate of 73.7% and an overall survival (OS) rate of 86.0%. No data cutoff date or patient number was disclosed in the press release for this study. The SHINE trial, now cleared to enrol in the United States, targets a narrower population: children with relapsed or refractory HRNB.

Daretabart binds GD2, a disialoganglioside cell-surface antigen expressed at high density on neuroblastoma cells. The antibody is designed to enhance immune-mediated tumour cell killing. Renaissance Pharma states that the molecule incorporates structural modifications intended to improve its tolerability profile relative to earlier-generation anti-GD2 antibodies, though no technical characterisation of those modifications — such as Fc engineering specifics or comparative binding data — was disclosed in the announcement. The company also confirmed that the first commercial-scale Good Manufacturing Practice (GMP) batch of Daretabart has been produced for use in the SHINE trial.

Research context

Neuroblastoma accounts for 7%-10% of all childhood cancers and is the most common extracranial solid tumour in children under one year of age. Approximately 800 new cases are diagnosed annually in the United States and more than 1,500 in Europe. Roughly 50% of all neuroblastoma patients present with high-risk disease, which carries a five-year overall survival rate of approximately 50% despite multimodal treatment — comprising induction chemotherapy, surgery, high-dose consolidation with autologous stem cell rescue, radiotherapy, and maintenance immunotherapy.

The current standard of care in HRNB already includes anti-GD2 monoclonal antibody therapy. Dinutuximab (Unituxin, United Therapeutics) received FDA approval in 2015 for pediatric patients with HRNB who had achieved at least a partial response to prior first-line multiagent, multimodal therapy. Dinutuximab beta (Qarziba, EUSA Pharma) holds European approval. Both agents target GD2 and are associated with infusion-related pain, a consequence of GD2 expression on peripheral nerve fibres. Renaissance Pharma’s claim that Daretabart incorporates modifications to improve tolerability positions the antibody as a potential successor in the same mechanistic class, though head-to-head comparative data are not yet available.

The relapsed or refractory HRNB setting targeted by the SHINE trial remains without a dedicated approved therapy, and response rates to salvage regimens in this population are low. The five-year survival for patients who relapse after standard therapy is estimated at below 10% in published literature, establishing the basis for the FDA’s recognition of unmet medical need in granting Fast Track status.